美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Septerna, Inc.

14.67

+0.24001.66%

盘后：14.670.00000.00%19:32 EDT

成交量：18.21万

成交额：265.39万

市值：6.54亿

市盈率：-5.16

高：14.77

开：14.46

低：14.22

收：14.43

52周最高：28.99

52周最低：4.17

股本：4,458.51万

流通股本：1,820.27万

量比：0.55

换手率：1.00%

股息：- -

股息率：- -

每股收益(TTM):-2.8438

每股收益(LYR):-7.2588

净资产收益率：-32.78%

总资产收益率：-21.58%

市净率：1.73

市盈率(LYR):-2.02

数据加载中...

总览公司新闻公告

Renovaro Inc.盘中异动股价大涨6.50%报0.357美元

Ars Pharmaceuticals, Inc.盘中异动早盘股价大跌6.97%

Omniab, Inc.盘中异动股价大涨5.00%报1.47美元

开盘 | 美股高开！超微电脑涨超18%，AMD涨超6%，Septerna暴涨63%

老虎资讯综合

Septerna盘前大涨70%！诺和诺德口服小分子减肥药牵手成功

BUZZ--美国股票走势-PVH、芯片公司、MP 材料公司

盘前异动 | Septerna暴涨63%，将与诺和诺德合作开发口服减肥药

美股异动 | Septerna(SEPN.US)盘前大涨67% 将与诺和诺德合作开发口服减肥药

智通财经网

诺和诺德与Septerna达成22亿美元协议共同开发新一代减重口服药

Septerna盘前涨超65% 与诺和诺德合作开发针对肥胖及其他心代谢疾病的口服小分子药物

诺和诺德与美国生物技术公司Septerna达成合作许可协议，将共同开发肥胖症等疾病药物

BUZZ-赛普特纳因 22 亿美元的诺和诺德交易而大涨

诺和诺德与Septerna达成22亿美元协议共同开发新型肥胖症治疗方法

诺和诺德与 Septerna 达成 22 亿美元协议，开发肥胖症新疗法

Septerna, Inc.2024财年实现净利润-71.80百万美元，同比减少12763.14%

富国银行：维持Septerna评级，由持股观望调整至持股观望评级, 目标价由14.00美元调整至11.00美元。

美国研究综述-应用材料公司、KLA、牛津工业公司

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/SEPN/news?page=3"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SEPN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SEPN\",,,,,undefined,":{"symbol":"SEPN","market":"US","secType":"STK","nameCN":"Septerna, Inc.","latestPrice":14.67,"timestamp":1757361600000,"preClose":14.43,"halted":0,"volume":182123,"hourTrading":{"tag":"盘后","latestPrice":14.67,"preClose":14.67,"latestTime":"19:32 EDT","volume":2476,"amount":36319.23,"timestamp":1757374367963},"delay":0,"floatShares":18202732,"shares":44585135,"eps":-2.843766,"marketStatus":"已收盘","change":0.24,"latestTime":"09-08 16:00:00 EDT","open":14.46,"high":14.765,"low":14.2152,"amount":2653933.873338,"amplitude":0.038101,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.843766,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1757404800000},"marketStatusCode":5,"adr":0,"listingDate":1729828800000,"exchange":"NASDAQ","adjPreClose":14.43,"preHourTrading":{"tag":"盘前","latestPrice":14.43,"preClose":14.43,"latestTime":"08:46 EDT","volume":26,"amount":375.18,"timestamp":1757335594955},"postHourTrading":{"tag":"盘后","latestPrice":14.67,"preClose":14.67,"latestTime":"19:32 EDT","volume":2476,"amount":36319.23,"timestamp":1757374367963},"volumeRatio":0.545478,"impliedVol":0.5138,"impliedVolPercentile":0.1259},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SEPN\",,,,,undefined,":{"symbol":"SEPN","floatShares":18202732,"roa":"-21.58%","roe":"-32.78%","lyrEps":-7.258829,"volumeRatio":0.545478,"shares":44585135,"dividePrice":0,"high":14.765,"amplitude":0.038101,"preClose":14.43,"low":14.2152,"week52Low":4.17,"pbRate":"1.73","psRate":"900.91","week52High":28.99,"institutionHeld":0,"latestPrice":14.67,"eps":-2.843766,"divideRate":0,"volume":182123,"delay":0,"ttmEps":-2.843766,"open":14.46,"prevYearClose":22.9,"prevWeekClose":14.43,"prevMonthClose":12.1,"prevQuarterClose":10.57,"fiveDayClose":12.1,"twentyDayClose":11.69,"sixtyDayClose":10.28},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SEPN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-11","symbol":"SEPN","fiscalQuarterEnding":"2025/06","expectedEps":-0.05,"name":null,"time":"盘后","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"post","actualEps":-0.56},{"market":"US","date":"2025-05-15","symbol":"SEPN","fiscalQuarterEnding":"2025/03","expectedEps":-0.38,"name":null,"time":"盘后","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2025-03-27","symbol":"SEPN","fiscalQuarterEnding":"2024/12","expectedEps":-0.69,"name":null,"time":"盘前","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"pre","actualEps":-0.64}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SEPN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SEPN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.8,"hold":0.2,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8,"analysts":5,"updateTime":1750910400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SEPN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SEPN","date":"2025-09-05","current":-7.194356,"percent":0.41784,"low":-71.269737,"twenty":-46.300716,"median":-6.581688,"eighty":-4.297053,"high":261.261398,"avg":-0.599732,"sd":73.430714,"marketCap":629542106},"quantilePoints":[{"date":"2024-10-25","current":180.873276,"twenty":180.873276,"median":180.873276,"eighty":180.873276,"marketCap":756050292},{"date":"2024-10-31","current":204.688257,"twenty":197.111676,"median":204.688257,"eighty":209.813,"marketCap":855596913},{"date":"2024-11-08","current":261.261398,"twenty":203.984861,"median":216.997688,"eighty":242.57116,"marketCap":1092072644},{"date":"2024-11-15","current":224.885772,"twenty":207.743006,"median":230.613426,"eighty":256.156752,"marketCap":940022529},{"date":"2024-11-22","current":-56.371082,"twenty":203.984861,"median":228.503238,"eighty":245.706296,"marketCap":915240881},{"date":"2024-11-29","current":-69.163916,"twenty":-57.105794,"median":221.92146,"eighty":240.581553,"marketCap":1122945345},{"date":"2024-12-06","current":-68.890433,"twenty":-66.926823,"median":208.506693,"eighty":237.707678,"marketCap":1118505070},{"date":"2024-12-13","current":-61.725172,"twenty":-67.501138,"median":191.022276,"eighty":236.763117,"marketCap":1002169886},{"date":"2024-12-20","current":-63.995083,"twenty":-66.784612,"median":-58.207863,"eighty":234.592638,"marketCap":1039024162},{"date":"2024-12-27","current":-70.449288,"twenty":-68.420042,"median":-60.166317,"eighty":232.180994,"marketCap":1143814633},{"date":"2025-01-03","current":-58.388676,"twenty":-68.655237,"median":-61.232902,"eighty":229.769351,"marketCap":947998541},{"date":"2025-01-10","current":-57.02126,"twenty":-67.714455,"median":-60.412452,"eighty":226.39305,"marketCap":925797170},{"date":"2025-01-17","current":-46.437457,"twenty":-67.358927,"median":-58.853597,"eighty":224.885772,"marketCap":753958559},{"date":"2025-01-24","current":-50.266223,"twenty":-66.593173,"median":-57.614562,"eighty":220.142874,"marketCap":816122397},{"date":"2025-01-31","current":-48.433885,"twenty":-66.401735,"median":-55.982023,"eighty":215.822012,"marketCap":786372560},{"date":"2025-02-07","current":-38.861971,"twenty":-65.110894,"median":-50.840537,"eighty":209.813,"marketCap":630962963},{"date":"2025-02-14","current":-31.587316,"twenty":-64.153703,"median":-49.199638,"eighty":205.451944,"marketCap":512851670},{"date":"2025-02-21","current":-16.108164,"twenty":-63.748948,"median":-46.492154,"eighty":202.578068,"marketCap":261532150},{"date":"2025-02-28","current":-15.862029,"twenty":-63.55204,"median":-46.410109,"eighty":188.992476,"marketCap":257535903},{"date":"2025-03-07","current":-17.393535,"twenty":-63.169163,"median":-46.191322,"eighty":63.291545,"marketCap":282401439},{"date":"2025-03-14","current":-17.47558,"twenty":-62.928498,"median":-43.237703,"eighty":-15.145503,"marketCap":283733521},{"date":"2025-03-21","current":-16.81922,"twenty":-62.747999,"median":-39.764466,"eighty":-15.424456,"marketCap":273076863},{"date":"2025-03-28","current":-3.893469,"twenty":-62.08617,"median":-37.439858,"eighty":-15.424456,"marketCap":279543299},{"date":"2025-04-04","current":-3.590162,"twenty":-61.462628,"median":-35.44343,"eighty":-3.701581,"marketCap":257766476},{"date":"2025-04-11","current":-3.194007,"twenty":-61.271189,"median":-31.04035,"eighty":-3.397655,"marketCap":229323279},{"date":"2025-04-17","current":-3.707771,"twenty":-61.249311,"median":-18.610536,"eighty":-3.429843,"marketCap":266210551},{"date":"2025-04-25","current":-3.998698,"twenty":-60.904722,"median":-17.913153,"eighty":-3.49979,"marketCap":287098524},{"date":"2025-05-02","current":-4.419614,"twenty":-60.313998,"median":-17.530277,"eighty":-3.557975,"marketCap":317319421},{"date":"2025-05-09","current":-4.302005,"twenty":-59.827198,"median":-17.393535,"eighty":-3.586448,"marketCap":308875347},{"date":"2025-05-16","current":-5.700187,"twenty":-58.946582,"median":-17.1474,"eighty":-3.607494,"marketCap":450930380},{"date":"2025-05-23","current":-5.339701,"twenty":-58.316351,"median":-16.81922,"eighty":-3.64092,"marketCap":422413044},{"date":"2025-05-30","current":-5.553739,"twenty":-57.970542,"median":-16.682479,"eighty":-3.660728,"marketCap":439345212},{"date":"2025-06-06","current":-5.925491,"twenty":-56.891224,"median":-16.203883,"eighty":-3.697867,"marketCap":468753715},{"date":"2025-06-13","current":-5.863532,"twenty":-56.29327,"median":-16.053467,"eighty":-3.717675,"marketCap":463852298},{"date":"2025-06-20","current":-5.908593,"twenty":-55.982023,"median":-15.862029,"eighty":-3.757291,"marketCap":467416965},{"date":"2025-06-27","current":-6.122632,"twenty":-53.001056,"median":-15.383433,"eighty":-3.77586,"marketCap":484349134},{"date":"2025-07-03","current":-6.404261,"twenty":-51.513306,"median":-10.750269,"eighty":-3.795668,"marketCap":506628303},{"date":"2025-07-11","current":-6.578872,"twenty":-50.660039,"median":-6.404261,"eighty":-3.874899,"marketCap":520441387},{"date":"2025-07-18","current":-7.108336,"twenty":-50.32092,"median":-6.590137,"eighty":-3.893469,"marketCap":562326225},{"date":"2025-07-25","current":-7.6378,"twenty":-49.412955,"median":-6.753482,"eighty":-3.9727,"marketCap":604211063},{"date":"2025-08-01","current":-6.990051,"twenty":-48.587036,"median":-6.961888,"eighty":-3.99746,"marketCap":552968974},{"date":"2025-08-08","current":-6.590137,"twenty":-46.8805,"median":-6.764747,"eighty":-3.998698,"marketCap":521332554},{"date":"2025-08-15","current":-5.951139,"twenty":-46.492154,"median":-6.643647,"eighty":-4.11805,"marketCap":520754376},{"date":"2025-08-22","current":-5.961329,"twenty":-46.448396,"median":-6.601402,"eighty":-4.167728,"marketCap":521646079},{"date":"2025-08-29","current":-6.256848,"twenty":-46.3937,"median":-6.581688,"eighty":-4.266238,"marketCap":547505457},{"date":"2025-09-05","current":-7.194356,"twenty":-46.300716,"median":-6.581688,"eighty":-4.297053,"marketCap":629542106}],"updateTime":1757379443588},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SEPN\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2535078719","title":"Renovaro Inc.盘中异动 股价大涨6.50%报0.357美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2535078719","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535078719?lang=zh_cn&edition=fundamental","pubTime":"2025-05-14 21:31","pubTimestamp":1747229510,"startTime":"0","endTime":"0","summary":"北京时间2025年05月14日21时31分，Renovaro Inc.股票出现波动，股价急速上涨6.50%。截至发稿，该股报0.357美元/股，成交量24.2908万股，换手率0.15%，振幅2.98%。Renovaro Inc.股票所在的生物技术行业中，整体涨幅为0.16%。其相关个股中，Septerna, Inc.、蓝鸟生物、Quoin Pharmaceuticals Ltd涨幅较大，Nucana Plc、Quoin Pharmaceuticals Ltd、Polyrizon Ltd.较为活跃，换手率分别为1898.41%、1175.43%、1053.77%，振幅较大的相关个股有Nucana Plc、Septerna, Inc.、Quoin Pharmaceuticals Ltd，振幅分别为20.97%、15.45%、14.94%。Renovaro Inc.公司简介：Renovaro Inc 是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051421315394f6c7bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051421315394f6c7bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RENB","SEPN","BK4007","BK4139"],"gpt_icon":0},{"id":"2535020188","title":"Ars Pharmaceuticals, Inc.盘中异动 早盘股价大跌6.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2535020188","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535020188?lang=zh_cn&edition=fundamental","pubTime":"2025-05-14 21:31","pubTimestamp":1747229508,"startTime":"0","endTime":"0","summary":"北京时间2025年05月14日21时31分，Ars Pharmaceuticals, Inc.股票出现波动，股价大幅下挫6.97%。Ars Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.16%。其相关个股中，Septerna, Inc.、蓝鸟生物、Quoin Pharmaceuticals Ltd涨幅较大，Nucana Plc、Quoin Pharmaceuticals Ltd、Polyrizon Ltd.较为活跃，换手率分别为1898.41%、1175.43%、1053.77%，振幅较大的相关个股有Nucana Plc、Septerna, Inc.、Quoin Pharmaceuticals Ltd，振幅分别为20.97%、15.45%、14.94%。Ars Pharmaceuticals, Inc.公司简介：ARS Pharmaceuticals Inc是一家生物制药公司，专注于开发用于紧急治疗 I 型过敏反应的新型、潜在全新候选产品 neffy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250514213148a47e3e47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250514213148a47e3e47&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SEPN","SPRY","BK4007"],"gpt_icon":0},{"id":"2535076191","title":"Omniab, Inc.盘中异动 股价大涨5.00%报1.47美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2535076191","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535076191?lang=zh_cn&edition=fundamental","pubTime":"2025-05-14 21:31","pubTimestamp":1747229475,"startTime":"0","endTime":"0","summary":"北京时间2025年05月14日21时31分，Omniab, Inc.股票出现异动，股价大幅拉升5.00%。截至发稿，该股报1.47美元/股，成交量3.1339万股，换手率0.03%，振幅0.71%。Omniab, Inc.股票所在的生物技术行业中，整体涨幅为0.16%。其相关个股中，Septerna, Inc.、蓝鸟生物、Quoin Pharmaceuticals Ltd涨幅较大，Nucana Plc、Quoin Pharmaceuticals Ltd、Polyrizon Ltd.较为活跃，换手率分别为1836.61%、1168.81%、1045.79%，振幅较大的相关个股有Quoin Pharmaceuticals Ltd、Nucana Plc、Septerna, Inc.，振幅分别为14.94%、9.12%、8.62%。Omniab, Inc.公司简介：OmniAb Inc 提供治疗性抗体发现技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051421311694f6c786&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051421311694f6c786&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","BK4007","OABI","SEPN"],"gpt_icon":0},{"id":"1115149243","title":"开盘 |  美股高开！超微电脑涨超18%，AMD涨超6%，Septerna暴涨63%","url":"https://stock-news.laohu8.com/highlight/detail?id=1115149243","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115149243?lang=zh_cn&edition=fundamental","pubTime":"2025-05-14 21:30","pubTimestamp":1747229418,"startTime":"0","endTime":"0","summary":"5月14日，美股三大指数集体高开，纳指涨0.34%，道指涨0.18%，标普500指数涨0.21%。美股AI概念股走高，AMD涨超6%，此前宣布60亿美元的回购计划；英伟达涨超2%，BigBear.ai控股涨超10%。AMD涨超6%，宣布新的60亿美元股票回购计划。超微电脑涨超18%，与DataVolt达成200亿美元合作协议。Septerna暴涨63%，将与诺和诺德合作开发口服减肥药。Aurora重挫17%，股东优步拟定增10亿美元可转换票据。美鹰服饰跌超9%，Q1业绩疲软并撤回2025财年业绩指引。","market":"us","thumbnail":"https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"908d74a800689522666d3aa33d9086ee","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMCI","LU0823434740.USD","LU1316542783.SGD","GFS","AMD","IE0009356076.USD","LU1303367103.USD","LU1880398471.USD","LU2458330169.SGD","BK4529","BK4512","LU2054465674.USD","LU0127658192.USD",".DJI","LU1880398554.USD","LU1923623000.USD","LU1861220033.SGD","SEPN","LU1951200564.SGD","BK4170","LU2098885051.SGD",".SPX",".IXIC"],"gpt_icon":0},{"id":"2535288663","title":"Septerna盘前大涨70%！诺和诺德口服小分子减肥药牵手成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2535288663","media":"Jo的随笔","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535288663?lang=zh_cn&edition=fundamental","pubTime":"2025-05-14 21:22","pubTimestamp":1747228921,"startTime":"0","endTime":"0","summary":"诺和诺德最终在小分子口服减肥药赛道，选择了Septerna。根据协议，Septerna 将从诺和诺德获得约 22 亿美元预付款及研发和商业里程碑付款，其中包括超 2 亿美元的预付款和近期里程碑付款。此外，Septerna 还将获得已上市产品全球净销售额的分级特许权使用费。Septerna 有权选择参与合作中一项项目的全球利润分成，替代该产品候选物未来的里程碑付款和特许权使用费。歌礼all in小分子口服减肥药，高剂量临床结果呼之欲出！","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515055837a47ea9cf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"30e0cbc36438ac0be975e41ae2b7cc35","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515055837a47ea9cf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","BK4599","IE00BKVL7J92.USD","LU1093756168.USD","SEPN","BK4588","LU1093756325.SGD","NVO","BK4007","BK4532","BK4585","LU0154236417.USD"],"gpt_icon":1},{"id":"2535742024","title":"BUZZ--美国股票走势-PVH、芯片公司、MP 材料公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2535742024","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535742024?lang=zh_cn&edition=fundamental","pubTime":"2025-05-14 21:07","pubTimestamp":1747228042,"startTime":"0","endTime":"0","summary":"nL6N3RM0LE ** Merck & Co Inc < MRK.N  >:BUZZ - 花旗因Keytruda专利悬崖和增长前景下调默克公司评级 nL6N3RM0LS ** KKR & Co Inc < KKR.N  >:BUZZ - 在摩根士丹利将其评级上调至 \"增持 \"后上涨 nL6N3RM0LU ** AbbVie Inc < ABBV.N  >:BUZZ - 花旗因美国政策风险和管道问题下调 AbbVie 评级 nL4N3RM0ZY ** Rivian Automotive Inc < RIVN.O  >:BUZZ - Jefferies 以需求担忧为由下调 Rivian 评级 nL6N3RM0ML ** Dynatrace Inc < DT.N  >:BUZZ - 因财政年度预测超出预期而上涨 nL4N3RM10Q ** Septerna Inc < SEPN.O  >:BUZZ - 因 22 亿美元的诺和诺德交易而飙升 nL4N3RM11S ** Forge Global Holdings Inc < FRGE.N  >:BUZZ - J.P. Morgan 将 Forge Global 的评级上调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nL4S3RM16O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DT","AUR","SEPN","ABBV","LU0965508806.USD","NVDD","2NVD.UK","LU1778281490.HKD","NVD","MP","BK4534","NVDS.UK","LU0265550946.USD","HTZ","NVDS","NVDU","IE00BKDWB100.SGD","LU1064131342.USD","PVH","LU0274383776.USD","SNVD.UK","NVIW.SI","LU0289739343.SGD","HK0000320223.HKD","NEM","SG9999015986.USD","AEO","3NVD.UK","LU2462611646.USD","CG","NVDX","KKR","GPI","NXT","LU1923623000.USD","NVD2.UK","NVD3.UK","NVDY","LU0081259029.USD","LU0957791311.USD","JCI","FRGE","BK4516"],"gpt_icon":1},{"id":"2535029024","title":"盘前异动 | Septerna暴涨63%，将与诺和诺德合作开发口服减肥药","url":"https://stock-news.laohu8.com/highlight/detail?id=2535029024","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535029024?lang=zh_cn&edition=fundamental","pubTime":"2025-05-14 20:42","pubTimestamp":1747226528,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺和诺德同意与Septerna共同开发和商业化用于治疗肥胖症和其他心脏代谢疾病的口服小分子药物，交易价值高达22亿美元。受该消息影响，Septerna盘前大涨67%。作为交易的一部分，该公司将从诺和诺德获得超过2亿美元的预付款和近期里程碑付款。诺和诺德向Septerna支付的总金额可能达到22亿美元，包括预付款以及研发和商业里程碑付款。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"30e0cbc36438ac0be975e41ae2b7cc35","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1293255.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Septerna将与诺和诺德合作开发口服减肥药","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4599","BK4588","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","SEPN","BK4532","BK4585","LU1093756168.USD","LU0154236417.USD","NVO","LU1093756325.SGD","BK4007"],"gpt_icon":0},{"id":"2535602161","title":"美股异动 | Septerna(SEPN.US)盘前大涨67% 将与诺和诺德合作开发口服减肥药","url":"https://stock-news.laohu8.com/highlight/detail?id=2535602161","media":"智通财经网","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535602161?lang=zh_cn&edition=fundamental","pubTime":"2025-05-14 20:34","pubTimestamp":1747226040,"startTime":"0","endTime":"0","summary":"诺和诺德同意与Septerna共同开发和商业化用于治疗肥胖症和其他心脏代谢疾病的口服小分子药物，交易价值高达22亿美元。受该消息影响，Septerna盘前大涨67%。作为交易的一部分，该公司将从诺和诺德获得超过2亿美元的预付款和近期里程碑付款。诺和诺德向Septerna支付的总金额可能达到22亿美元，包括预付款以及研发和商业里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"30e0cbc36438ac0be975e41ae2b7cc35","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-05-14/doc-inewpwew0285573.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4532","BK4599","BK4585","IE00BKVL7J92.USD","SEPN","LU1093756168.USD","LU1093756325.SGD","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4588","BK4007"],"gpt_icon":1},{"id":"2535211680","title":"诺和诺德与Septerna达成22亿美元协议 共同开发新一代减重口服药","url":"https://stock-news.laohu8.com/highlight/detail?id=2535211680","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535211680?lang=zh_cn&edition=fundamental","pubTime":"2025-05-14 20:32","pubTimestamp":1747225926,"startTime":"0","endTime":"0","summary":"格隆汇5月14日｜诺和诺德周三宣布，与美国生物技术公司Septerna达成价值高达22亿美元的合作与授权协议，将共同开发针对肥胖、第二型糖尿病及其他心脏代谢疾病的口服小分子新药。这笔交易包含超过2亿美元的预付款及短期付款，未来潜在价值最高可达22亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250514203218975976fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"30e0cbc36438ac0be975e41ae2b7cc35","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250514203218975976fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","BK4599","LU1093756325.SGD","IE00BZ1G4Q59.USD","LU1093756168.USD","LU0154236417.USD","BK4588","IE00BKVL7J92.USD","BK4585","BK4007","SEPN","NVO"],"gpt_icon":0},{"id":"2535298400","title":"Septerna盘前涨超65% 与诺和诺德合作开发针对肥胖及其他心代谢疾病的口服小分子药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2535298400","media":"金吾资讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535298400?lang=zh_cn&edition=fundamental","pubTime":"2025-05-14 20:20","pubTimestamp":1747225205,"startTime":"0","endTime":"0","summary":"金吾财讯 | Septerna(SEPN)盘前股价暴力拉升，暂涨65.92%，报11.16美元。消息面上，公司与诺和诺德达成合作与许可协议，共同开发用于治疗肥胖症、2型糖尿病和其他心脏代谢疾病的口服小分子药物。诺和诺德是广受欢迎的减肥药Wegovy的制造商，该公司试图通过开发下一代药物、收购和合作来进一步巩固其在潜在的1500亿美元肥胖症市场中的地位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051420204294f6b68a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"30e0cbc36438ac0be975e41ae2b7cc35","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051420204294f6b68a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","BK4588","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","SEPN","BK4532","BK4585","LU1093756168.USD","LU0154236417.USD","NVO","LU1093756325.SGD","BK4007"],"gpt_icon":0},{"id":"2535025717","title":"诺和诺德与美国生物技术公司Septerna达成合作许可协议，将共同开发肥胖症等疾病药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2535025717","media":"界面","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535025717?lang=zh_cn&edition=fundamental","pubTime":"2025-05-14 19:53","pubTimestamp":1747223589,"startTime":"0","endTime":"0","summary":"5月14日，诺和诺德公司宣布，其与美国生物技术公司Septerna达成了一项合作与许可协议，将共同开发治疗肥胖症、2型糖尿病和其他心血管疾病的口服小分子药物。诺和诺德表示，Septerna公司将有资格获得约22亿美元的收益，其中包括超2亿美元的前期和近期付款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250514195309a6deea57&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"30e0cbc36438ac0be975e41ae2b7cc35","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250514195309a6deea57&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","LU0154236417.USD","LU1093756168.USD","NVO","BK4532","LU1093756325.SGD","SEPN","IE00BKVL7J92.USD","BK4588","BK4007","BK4585","BK4599"],"gpt_icon":0},{"id":"2535902356","title":"BUZZ-赛普特纳因 22 亿美元的诺和诺德交易而大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2535902356","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535902356?lang=zh_cn&edition=fundamental","pubTime":"2025-05-14 19:43","pubTimestamp":1747223015,"startTime":"0","endTime":"0","summary":"5月14日 - ** 药物开发商Septerna SEPN.O的股价盘前上涨63.3%至10.99美元** 丹麦制药商诺和诺德NOVOb.CO与SEPN合作开发治疗肥胖症和糖尿病的口服药物，交易价值高达22亿美元 。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"30e0cbc36438ac0be975e41ae2b7cc35","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nL4T3RM124:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN","BK4007"],"gpt_icon":0},{"id":"2535461023","title":"诺和诺德与Septerna达成22亿美元协议 共同开发新型肥胖症治疗方法","url":"https://stock-news.laohu8.com/highlight/detail?id=2535461023","media":"金吾资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535461023?lang=zh_cn&edition=fundamental","pubTime":"2025-05-14 19:42","pubTimestamp":1747222978,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺和诺德(NVO)周三表示，已与美国生物技术公司Septerna达成合作与许可协议，共同开发用于治疗肥胖症、2型糖尿病和其他心脏代谢疾病的口服小分子药物。诺和诺德是广受欢迎的减肥药Wegovy的制造商，该公司试图通过开发下一代药物、收购和合作来进一步巩固其在潜在的1500亿美元肥胖症市场中的地位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051419444594f6ae1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"30e0cbc36438ac0be975e41ae2b7cc35","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051419444594f6ae1d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","BK4007","NVO","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","SEPN","LU1093756168.USD","LU1093756325.SGD","BK4585","BK4532","LU0154236417.USD","BK4588"],"gpt_icon":0},{"id":"2535042936","title":"诺和诺德与 Septerna 达成 22 亿美元协议，开发肥胖症新疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2535042936","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535042936?lang=zh_cn&edition=fundamental","pubTime":"2025-05-14 19:00","pubTimestamp":1747220407,"startTime":"0","endTime":"0","summary":"路透哥本哈根5月14日 - 诺和诺德公司与美国生物技术公司Septerna  达成了一项合作与许可协议，共同开发治疗肥胖症、2型糖尿病和其他心血管代谢疾病的口服小分子药物，双方周三表示，Septerna公司的合作价值可达22亿美元。两家公司表示，新的合作关系包括为Septerna SEPN.O支付2亿多美元的前期和近期款项。今年 3 月，罗氏公司表示 ，它将支付高达 53 亿美元的费用，共同开发和共同销售 Zealand Pharma 公司的肥胖症候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"30e0cbc36438ac0be975e41ae2b7cc35","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nL4T3RM0ZP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0097036916.USD","LU1267930730.SGD","LU1712237335.SGD","LU0114720955.EUR","IE00BJJMRZ35.SGD","IE00B1BXHZ80.USD","IE00BJLML261.HKD","IE00BJT1NW94.SGD","IE00BK4W5M84.HKD","SGXZ57979304.SGD","LU0266013472.USD","LU0466842654.USD","LU0106261372.USD","IE00BSNM7G36.USD","IE0004091025.USD","LU2237443465.HKD","LU2237438978.USD","LU1868837300.USD","LU1668664300.SGD","LU1093756168.USD","LU0320765992.SGD","LU1868836757.USD","LU2360106947.USD","LU0251131958.USD","LU0289739699.SGD","LU2237443622.USD","LU1023059063.AUD","LU2552382058.USD","SG9999014914.USD","LU2112291526.USD","LU2361044949.HKD","SG9999001176.SGD","LU2264538146.SGD","IE00B4R5TH58.HKD","SG9999001176.USD","LU1035775433.USD","LU1232071149.USD","LU2468319806.SGD","LU2089984988.USD","LU2471134952.CNY","LU2491049909.HKD","SG9999018865.SGD","BK4504","IE0034235188.USD","SGXZ31699556.SGD","LU0198837287.USD","LU2750360641.GBP","SEPN","LU0048573561.USD"],"gpt_icon":1},{"id":"2523692486","title":"Septerna, Inc.2024财年实现净利润-71.80百万美元，同比减少12763.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2523692486","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523692486?lang=zh_cn&edition=fundamental","pubTime":"2025-03-29 14:00","pubTimestamp":1743228033,"startTime":"0","endTime":"0","summary":"3月29日，Septerna, Inc.公布财报，公告显示公司2024财年净利润为-71.80百万美元，同比减少12763.14%；其中营业收入为1.08百万美元，同比增加615.23%，每股基本收益为-1.62美元。从资产负债表来看，Septerna, Inc.总负债36.51百万美元，其中短期债务1.85百万美元，资产负债比为0.13，流动比率为0.28。机构评级：截至2025年3月29日，当前有3家机构对Septerna, Inc.目标价做出预测，其中目标均价为19.33美元，其中最低目标价为11.00美元，最高目标价为27.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250329140037a4462f16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250329140037a4462f16&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SEPN"],"gpt_icon":0},{"id":"2522506567","title":"富国银行：维持Septerna评级，由持股观望调整至持股观望评级, 目标价由14.00美元调整至11.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2522506567","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522506567?lang=zh_cn&edition=fundamental","pubTime":"2025-03-28 22:21","pubTimestamp":1743171697,"startTime":"0","endTime":"0","summary":"富国银行：维持Septerna(SEPN.US)评级，由持股观望调整至持股观望评级, 目标价由14.00美元调整至11.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025032822260994c45623&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025032822260994c45623&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SEPN"],"gpt_icon":0},{"id":"2522011511","title":"美国研究综述-应用材料公司、KLA、牛津工业公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2522011511","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522011511?lang=zh_cn&edition=fundamental","pubTime":"2025-03-28 15:22","pubTimestamp":1743146579,"startTime":"0","endTime":"0","summary":"美国研究综述-应用材料公司、KLA、牛津工业公司路透社3月28日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括应用材料公司、KLA公司和牛津工业公司。要闻  * 应用材料公司AMAT.O：杰富瑞将其评级从 \"持有 \"上调至 \"买入 * KLA Corp KLAC.O：杰富瑞将其评级从 \"买入 \"下调至 \"持有 * Oxford Industries Inc OXM.N：KeyBanc将其行业权重从增持下调至减持 以下是路透社周五报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL3S3QB0JE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OXM","FUL","SNX","LU0320765489.SGD","SEPN","LU0476273544.USD","LU1267930813.SGD","LU0354030438.USD","MMSI","LU0208291251.USD","LU1674673691.USD","IE00BSNM7G36.USD","LU2028103732.USD","BRZE","BK4547","LRCX","LU0158827781.USD","ONTO","BK4109","LU0158827948.USD","LU0300736492.USD","LU2125154778.USD","IE00B3CCJ963.GBP","LU0889566641.SGD","LU1923623000.USD","KLAC","LU0170899867.USD","LU0957808578.USD","LU0368265418.SGD","LU2065731478.USD","IE00BLSP4239.USD","IE00BD6J9T35.USD","AMAT","OWL","BK4135","LU1642822529.SGD","NCNO","LU2125154935.USD","LU1674673428.USD","LU2106854487.HKD","IE00B7KXQ091.USD","IE00BN8TJ469.HKD","IE00BQXX3D17.EUR","LU0957791311.USD","LU0456854461.SGD","LU1815336760.USD","PVH","EOG","LU0868494617.USD","LU2458330169.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":57,"code":"91000000","status":"200"}]}}